Body composition and quality of life in adults treated with GH therapy: A systematic review and meta-analysis

Ahmad Hazem, Mohamed B. Elamin, Irina Bancos, German Malaga, Gabriela Prutsky, Juan Pablo Domecq, Tarig A. Elraiyah, Nisrin O. Abu Elnour, Yolanda Prevost, Jaime PAlmandoz, Claudia Zeballos-Palacios, Edgar R. Velasquez, Patricia J. Erwin, Neena Natt, Victor Manuel Montori, Mohammad H Murad

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95% CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95%CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.

Original languageEnglish (US)
Pages (from-to)13-20
Number of pages8
JournalEuropean Journal of Endocrinology
Volume166
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Body Composition
Meta-Analysis
Quality of Life
Confidence Intervals
Adipose Tissue
Edema
Joints
Information Storage and Retrieval
Therapeutics
MEDLINE
Bone Density
Weight Loss
Body Mass Index
Randomized Controlled Trials
Placebos
Safety
Weights and Measures

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Body composition and quality of life in adults treated with GH therapy : A systematic review and meta-analysis. / Hazem, Ahmad; Elamin, Mohamed B.; Bancos, Irina; Malaga, German; Prutsky, Gabriela; Domecq, Juan Pablo; Elraiyah, Tarig A.; Abu Elnour, Nisrin O.; Prevost, Yolanda; PAlmandoz, Jaime; Zeballos-Palacios, Claudia; Velasquez, Edgar R.; Erwin, Patricia J.; Natt, Neena; Montori, Victor Manuel; Murad, Mohammad H.

In: European Journal of Endocrinology, Vol. 166, No. 1, 01.2012, p. 13-20.

Research output: Contribution to journalArticle

Hazem, A, Elamin, MB, Bancos, I, Malaga, G, Prutsky, G, Domecq, JP, Elraiyah, TA, Abu Elnour, NO, Prevost, Y, PAlmandoz, J, Zeballos-Palacios, C, Velasquez, ER, Erwin, PJ, Natt, N, Montori, VM & Murad, MH 2012, 'Body composition and quality of life in adults treated with GH therapy: A systematic review and meta-analysis', European Journal of Endocrinology, vol. 166, no. 1, pp. 13-20. https://doi.org/10.1530/EJE-11-0558
Hazem, Ahmad ; Elamin, Mohamed B. ; Bancos, Irina ; Malaga, German ; Prutsky, Gabriela ; Domecq, Juan Pablo ; Elraiyah, Tarig A. ; Abu Elnour, Nisrin O. ; Prevost, Yolanda ; PAlmandoz, Jaime ; Zeballos-Palacios, Claudia ; Velasquez, Edgar R. ; Erwin, Patricia J. ; Natt, Neena ; Montori, Victor Manuel ; Murad, Mohammad H. / Body composition and quality of life in adults treated with GH therapy : A systematic review and meta-analysis. In: European Journal of Endocrinology. 2012 ; Vol. 166, No. 1. pp. 13-20.
@article{965bda38d0a44df5bf10d00aa6f00477,
title = "Body composition and quality of life in adults treated with GH therapy: A systematic review and meta-analysis",
abstract = "Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95{\%} confidence interval (95{\%} CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95{\%} CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95{\%}CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95{\%} CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95{\%} CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.",
author = "Ahmad Hazem and Elamin, {Mohamed B.} and Irina Bancos and German Malaga and Gabriela Prutsky and Domecq, {Juan Pablo} and Elraiyah, {Tarig A.} and {Abu Elnour}, {Nisrin O.} and Yolanda Prevost and Jaime PAlmandoz and Claudia Zeballos-Palacios and Velasquez, {Edgar R.} and Erwin, {Patricia J.} and Neena Natt and Montori, {Victor Manuel} and Murad, {Mohammad H}",
year = "2012",
month = "1",
doi = "10.1530/EJE-11-0558",
language = "English (US)",
volume = "166",
pages = "13--20",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Body composition and quality of life in adults treated with GH therapy

T2 - A systematic review and meta-analysis

AU - Hazem, Ahmad

AU - Elamin, Mohamed B.

AU - Bancos, Irina

AU - Malaga, German

AU - Prutsky, Gabriela

AU - Domecq, Juan Pablo

AU - Elraiyah, Tarig A.

AU - Abu Elnour, Nisrin O.

AU - Prevost, Yolanda

AU - PAlmandoz, Jaime

AU - Zeballos-Palacios, Claudia

AU - Velasquez, Edgar R.

AU - Erwin, Patricia J.

AU - Natt, Neena

AU - Montori, Victor Manuel

AU - Murad, Mohammad H

PY - 2012/1

Y1 - 2012/1

N2 - Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95% CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95%CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.

AB - Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95% CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95%CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.

UR - http://www.scopus.com/inward/record.url?scp=84055199671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055199671&partnerID=8YFLogxK

U2 - 10.1530/EJE-11-0558

DO - 10.1530/EJE-11-0558

M3 - Article

C2 - 21865409

AN - SCOPUS:84055199671

VL - 166

SP - 13

EP - 20

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -